Rosa Camila Lucchetta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4312870/publications.pdf

Version: 2024-02-01

36 papers

300 citations

1305906 8 h-index 16 g-index

38 all docs 38 docs citations

38 times ranked 432 citing authors

#	Article	IF	CITATIONS
1	Methodological standards for conducting and reporting meta-analyses: Ensuring the replicability of meta-analyses of pharmacist-led medication review. Research in Social and Administrative Pharmacy, 2022, 18, 2259-2268.	1.5	9
2	Methodological quality and risk of bias of meta-analyses of pharmacy services: A systematic review. Research in Social and Administrative Pharmacy, 2022, 18, 2403-2409.	1.5	3
3	Cost-Effectiveness of Molecular Method Diagnostic for Rapid Detection of Antibiotic-Resistant Bacteria. Value in Health Regional Issues, 2022, 27, 12-20.	0.5	1
4	Deficiency and Insufficiency of Vitamin D in Women of Childbearing Age: A Systematic Review and Meta-analysis. Revista Brasileira De Ginecologia E Obstetricia, 2022, 44, 409-424.	0.3	2
5	Hospitalization costs of coronaviruses diseases in upper-middle-income countries: A systematic review. PLoS ONE, 2022, 17, e0265003.	1.1	7
6	Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE – Coalition V): A double-blind, multicentre, randomised, controlled trial. The Lancet Regional Health Americas, 2022, 11, 100243.	1.5	11
7	Cost of adverse drug events related to potentially inappropriate medication use: A systematic review. Journal of the American Pharmacists Association: JAPhA, 2022, 62, 1463-1476.e14.	0.7	5
8	A comprehensive look at explicit screening tools for potentially inappropriate medication: A systematic scoping review. Australasian Journal on Ageing, 2022, 41, 357-382.	0.4	8
9	Drug interactions for elderly people with mental and behavioral disorders: a systematic scoping review. Archives of Gerontology and Geriatrics, 2021, 93, 104283.	1.4	7
10	Genetic polymorphisms associated with upper gastrointestinal bleeding: a systematic review. Pharmacogenomics Journal, 2021, 21, 20-36.	0.9	10
11	Analysis of completeness for spontaneous reporting of disease-modifying therapies in multiple sclerosis. Expert Opinion on Drug Safety, 2021, 20, 1-6.	1.0	1
12	lodine deficiency in women of childbearing age in Brazil: systematic review and meta-analysis. Vitae, 2021, 28, .	0.2	1
13	Deficiency of vitamins C and E in women of childbearing age in Brazil: a systematic review and meta-analysis. Sao Paulo Medical Journal, 2021, 139, 545-555.	0.4	1
14	PossÃveis desfechos de longo prazo da Covid-19: uma revisÃ \pm o sistemÃ $_{i}$ tica de escopos. Journal of Health & Biological Sciences, 2021, 9, 1.	0.0	2
15	Efficacy outcomes reported in trials of multiple sclerosis: A systematic scoping review. Multiple Sclerosis and Related Disorders, 2020, 45, 102435.	0.9	3
16	Outcome measures for disease-modifying therapies in relapsing multiple sclerosis randomized clinical trials. JBI Evidence Synthesis, 2020, Publish Ahead of Print, 1781-1787.	0.6	3
17	Clinical pharmacy services in Brazil, particularly cardiometabolic diseases: a systematic scoping review and meta-analyses. Pharmacy Practice, 2020, 18, 2131.	0.8	2
18	Mapping the characteristics of meta-analyses of pharmacy services: a systematic review. International Journal of Clinical Pharmacy, 2020, 42, 1252-1260.	1.0	10

#	Article	IF	CITATIONS
19	Reliability in long-term clinical studies of disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review. PLoS ONE, 2020, 15, e0231722.	1.1	3
20	Drug interactions for elderly with respiratory disorders and times of COVID-19: a systematic scoping review. Vitae, 2020, 27, .	0.2	4
21	Title is missing!. , 2020, 15, e0231722.		O
22	Title is missing!. , 2020, 15, e0231722.		О
23	Title is missing!. , 2020, 15, e0231722.		O
24	Title is missing!. , 2020, 15, e0231722.		O
25	Title is missing!. , 2020, 15, e0231722.		O
26	Title is missing!. , 2020, 15, e0231722.		0
27	Safety outcomes of disease-modifying therapies for relapsing–remitting multiple sclerosis: A network meta-analysis. Multiple Sclerosis and Related Disorders, 2019, 35, 7-15.	0.9	15
28	Efficacy and safety of the pharmacotherapy used in the management of hyperkalemia: a systematic review. Pharmacy Practice, 2019, 17, 1361.	0.8	10
29	What would be a trigger tool with better performance for detecting drug-induced hyperkalemia?. Sao Paulo Medical Journal, 2019, 137, 386-387.	0.4	O
30	Brazilian Analytical Decision Model for Cardiovascular Disease: An Adaptation of the Scottish Cardiovascular Disease Policy Model. Value in Health Regional Issues, 2018, 17, 210-216.	0.5	2
31	Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: A Network Meta-Analysis. CNS Drugs, 2018, 32, 813-826.	2.7	50
32	Association between Development of Dementia and Use of Benzodiazepines: A Systematic Review and Metaâ€Analysis. Pharmacotherapy, 2018, 38, 1010-1020.	1.2	51
33	Diethylpropion and mazindol: An end to the discussion?. Revista Da Associação Médica Brasileira, 2017, 63, 203-206.	0.3	3
34	Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. Clinics, 2017, 72, 317-324.	0.6	37
35	Analysis of the discrepancies identified during medication reconciliation on patient admission in cardiology units: a descriptive study. Revista Latino-Americana De Enfermagem, 2016, 24, e2760.	0.4	7
36	Self-perception of knowledge and adherence reflecting the effectiveness of antiretroviral therapy. Patient Preference and Adherence, 2016, Volume 10, 1787-1793.	0.8	9